Speaker: DR.KRITHIKAA SEKAR, CONSULTANT RADIATION ONCOLOGIST, HCG BENGALURU INDIA
DR.KRITHIKAA SEKAR: Hi, this is Doctor Krithikaa Radiation oncologist from India HCG Bangalore. And I'm excited to be presenting at the ASTRO annual conference 2024. So our study is about gynecological cancer brachytherapy that is in cancer of the cervix, wherein we have compared two schedules of brachytherapy. The conventional approach of brachytherapy in cancer of the cervix is a weekly one's application. In contrast, if you look at sarcomas or oral cavity, whenever brachytherapy is indicated, it is always done as a single application, multifractionated delivery. So our research question was that, given the era of image-guided brachytherapy, wherein with precision we know the dose that goes to the organs at risk. In our case, it being the rectum, bladder and bowel. Why can't we still go ahead and do the single application multifractionated delivery? So ours is a real-world data non-inferiority study that compares about 401 patients that are split between the conventional approach versus the single application multifractionated delivery. And I can't wait to share the results with you all. Stay tuned
